Parp inhibitors are a class of targeted anti-cancer drugs that help block specific enzymes called poly ADP-ribose polymerases (PARPs) that are involved in DNA repair. By blocking PARPs, parp inhibitors allow for DNA damage to accumulate in cancer cells, which can lead to cell death. The main advantages of parp inhibitors are their high specificity for cancer cells which are deficient in DNA repair pathways like BRCA1 and BRCA2. This specificity allows parp inhibitors to selectively kill cancer cells while leaving normal cells unharmed. The growing need for more targeted, less toxic cancer therapies has driven research into parp inhibitors which are demonstrating efficacy in treating several cancer types like breast, ovarian and prostate cancers.

Key Takeaways

Key players operating in the Parp Inhibitor market are FLSmidth & Co. A/S, Metso Oyj, Koppern Group, CITIC Heavy Industries Co. Ltd. (CITIC HIC), ThyssenKrupp Industrial Solutions AG (Polysius AG), SGS S.A., KHD Humboldt Wedag International AG, Outotec Oyj, and ABB Ltd. The key opportunities in the market include the increasing approvals for new drug formulations and rising applications of parp inhibitors in combination with other anti-cancer therapies. Technological advancements like development of orally bioavailable parp inhibitor formulations and personalized medicines tailored for specific cancer mutations are further fueling market growth.

Market drivers

The rising prevalence of cancer worldwide coupled with the increasing focus on precision medicine-based cancer therapies are driving the PARP Inhibitor market Demand. As per estimates, over 18 million new cancer cases and 9.6 million cancer deaths occurred globally in 2018. Furthermore, the growing cognizance about BRCA gene mutations and their role in DNA damage repair has boosted the potential role of parp inhibitors in treating BRCA-mutated cancers. This is a major market driver increasing adoption of these drugs.

Current challenges in Parp Inhibitor Market

The Parp Inhibitor Market is facing few major challenges which include high costs associated with the research and development of more effective Parp inhibitors. The development of Parp inhibitors requires substantial financial investments and long clinical trials to prove their efficacy and safety. This increases the costs and risks involved. Another challenge is the shortage of skilled professionals in the field of drug development. Developing innovative Parp inhibitors requires collaboration of experts from various fields like oncology, molecular biology, medicinal chemistry etc. However, there is shortage of such multi-disciplinary talents which hinders the research progress. Addressing cancer heterogeneity and developing inhibitors which can target multiple cancer types is also a key challenge.

SWOT Analysis

Strength: Growing clinical evidence validating the role of Parp inhibitors in treatment of various cancers. Rising demand for personalized medicine and targeted therapies also boosts the market.

Weakness: High costs associated with development and regulatory approvals. Safety concerns regarding long term use.

Opportunity: Significant research to expand the applications of PARP Inhibitor Market Analysis in new cancer indications. Combination therapies with other anti-cancer drugs offer opportunities.

Threats: Competition from alternative targeted therapies. Generic erosion of blockbuster drugs impact profits of major players.

Get more insights on PARP Inhibitor Market